a study to investigate the effect of renal impairment on the pharmacokinetics and safety of vir-2218

Conditions: Renal Impairment

Summary: the rationale of this study is to evaluate the impact of renal function on the pk, safety, and tolerability of vir-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable

participants may be enrolled in cohorts 1 and 2 in a non-randomized way.

Eligibility criteria:
inclusion criteria for all participants: * participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (egfr) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first. * body mass index (bmi) within the range 18.5 to 40.0 kg/m\^2 at screening. * female and male participants must consent to follow contraception requirements * capability of giving signed informed consent form inclusion criteria: additional criteria specific to healthy participants: * must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations * must have normal renal function as defined by egfr ≥ 90 ml/min/1.73m\^2 based on the modification of diet in renal disease (mdrd) equation determined from the mean of two measurements of serum creatinine at screening. inclusion criteria: additional criteria specific to participants with renal impairment * participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations * participants with ri must have chronic moderate or severe ri and be clinically stable per investigator assessment for at least 3 months prior to screening * moderate ri as defined by egfr level 30-59 ml/min/1.73m\^2 based on the mdrd equation, or * severe ri as defined by egfr level 15-29ml/min/1.73m\^2 based on the mdrd equation exclusion criteria: criteria for all participants * any clinically significant medical condition or psychiatric condition that may interfere with study intervention * participants with uncontrolled hypertension, asthma, and/or diabetes (type i or ii). * participants with diabetes * participants with any active malignancy * participants with vasculitis or conditions associated with vasculitis. * participants who have undergone major surgery within 12 months of screening * participants with unstable cardiac functions, abnormality, or clinically significant heart failure * participants with infection of hiv, hav, hbv, hcv, hdv, or hev * participants with signs of active infection * history of bone marrow or solid organ transplantation * participants with end-stage renal disease or nephrotic syndrome as defined by: participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome * participants with active nephritis * participants with clinically significant liver disease * history of drug or alcohol abuse * unwillingness or inability to follow procedures outlined in protocol exclusion criteria: additional criteria specific to healthy participants * use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to d1 of study participation exclusion criteria: additional criteria specific to participants with renal impairment * not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration). use of other prescription medications or over-the-counter medications that are not for chronic conditions (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to d1 of study participation